Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Simeonov, Simeon
ML-ORI-201, NCT05599295 / 2022-001297-63: Study to Evaluate the Safety and Tolerability of Single-Dose Intravenous (IV) Oritavancin	Recruiting	2	200	Europe, US	Oritavancin	Melinta Therapeutics, LLC, Melinta Therapeutics, LLC	Acute Bacterial Skin and Skin Structure Infection	06/25	01/26